These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 21345545)

  • 1. Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug.
    Teixeira C; Gomes JR; Gomes P; Maurel F; Barbault F
    Eur J Med Chem; 2011 Apr; 46(4):979-92. PubMed ID: 21345545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association.
    Maerz AL; Drummer HE; Wilson KA; Poumbourios P
    J Virol; 2001 Jul; 75(14):6635-44. PubMed ID: 11413331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41.
    Jiang S; Debnath AK
    Biochem Biophys Res Commun; 2000 Mar; 269(3):641-6. PubMed ID: 10720469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformation of trimeric envelope glycoproteins: the CD4-dependent membrane fusion mechanism of HIV-1.
    Yingliang W; Hong Y; Zhijian C; Wenxin L
    J Biomol Struct Dyn; 2007 Aug; 25(1):1-9. PubMed ID: 17676933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in targeting HIV-1 entry.
    Ryser HJ; Flückiger R
    Drug Discov Today; 2005 Aug; 10(16):1085-94. PubMed ID: 16182193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New anti-HIV agents and targets.
    De Clercq E
    Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4 activation of HIV fusion.
    Sattentau QJ
    Int J Cell Cloning; 1992 Nov; 10(6):323-32. PubMed ID: 1281202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity.
    Jiang S; Debnath AK
    Biochem Biophys Res Commun; 2000 Apr; 270(1):153-7. PubMed ID: 10733920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 gp41: mediator of fusion and target for inhibition.
    Weiss CD
    AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4.
    Kazmierski WM; Kenakin TP; Gudmundsson KS
    Chem Biol Drug Des; 2006 Jan; 67(1):13-26. PubMed ID: 16492145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral properties of two trimeric recombinant gp41 proteins.
    Delcroix-Genête D; Quan PL; Roger MG; Hazan U; Nisole S; Rousseau C
    Retrovirology; 2006 Mar; 3():16. PubMed ID: 16515685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role for the disulfide-bonded region of human immunodeficiency virus type 1 gp41 in receptor-triggered activation of membrane fusion function.
    Bellamy-McIntyre AK; Bär S; Ludlow L; Drummer HE; Poumbourios P
    Biochem Biophys Res Commun; 2010 Apr; 394(4):904-8. PubMed ID: 20230797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.
    Lu L; Yu F; Cai L; Debnath AK; Jiang S
    Curr Top Med Chem; 2016; 16(10):1074-90. PubMed ID: 26324044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of the entry of HIV into host cells.
    Meanwell NA; Kadow JF
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):451-61. PubMed ID: 12951808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of envelope processing and gp41 membrane spanning domain in the formation of human immunodeficiency virus type 1 (HIV-1) fusion-competent envelope glycoprotein complex.
    Welman M; Lemay G; Cohen EA
    Virus Res; 2007 Mar; 124(1-2):103-12. PubMed ID: 17129629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential drug targets on the HIV-1 envelope glycoproteins, gp120 and gp41.
    Huang L; Zhang L; Chen CH
    Curr Pharm Des; 2003; 9(18):1453-62. PubMed ID: 12769725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120.
    Desmezieres E; Gupta N; Vassell R; He Y; Peden K; Sirota L; Yang Z; Wingfield P; Weiss CD
    J Virol; 2005 Apr; 79(8):4774-81. PubMed ID: 15795263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors.
    Pacheco B; Alsahafi N; Debbeche O; Prévost J; Ding S; Chapleau JP; Herschhorn A; Madani N; Princiotto A; Melillo B; Gu C; Zeng X; Mao Y; Smith AB; Sodroski J; Finzi A
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28003492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational study of fragments of envelope proteins (gp120: 254-274 and gp41: 519-541) of HIV-1 by NMR and MD simulations.
    Kanyalkar M; Srivastava S; Saran A; Coutinho E
    J Pept Sci; 2004 Jun; 10(6):363-80. PubMed ID: 15214441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.
    Liu S; Lu H; Niu J; Xu Y; Wu S; Jiang S
    J Biol Chem; 2005 Mar; 280(12):11259-73. PubMed ID: 15640162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.